CSL (OTCMKTS:CSLLY) Shares Up 6.3% – What’s Next?

CSL Limited Sponsored ADR (OTCMKTS:CSLLY) shot up 6.3% during mid-day trading on Wednesday . The stock traded as high as $18.19 and last traded at $18.15. 4,274 shares were traded during mid-day trading, a decline of 99% from the average session volume of 448,426 shares. The stock had previously closed at $17.08.

Analyst Ratings Changes

Several research firms have issued reports on CSLLY. Zacks Research lowered shares of CSL from a “hold” rating to a “strong sell” rating in a research report on Monday, May 11th. Canaccord Genuity Group downgraded shares of CSL from a “strong-buy” rating to a “hold” rating in a report on Monday, May 11th. Jefferies Financial Group downgraded shares of CSL from a “strong-buy” rating to a “hold” rating in a report on Friday, May 29th. Finally, Citigroup downgraded shares of CSL from a “strong-buy” rating to a “hold” rating in a report on Monday, May 11th. Four research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, CSL currently has a consensus rating of “Reduce”.

CSL Stock Up 6.6%

The business’s fifty day moving average price is $20.77 and its 200 day moving average price is $40.12. The company has a current ratio of 2.57, a quick ratio of 1.15 and a debt-to-equity ratio of 0.51.

CSL Company Profile

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.